The role of human papillomavirus deoxyribonucleic acid for distinguishing between cervical adenocarcinoma and endometrial adenocarcinoma
Downloads
HIGHLIGHTS
1. Determining primary tumor between uterine cervical adenocarcinoma and endometrial carcinoma is often complicated due to the lack of specimen or overlapped histological and morphological spectrum.
2. The distinction between endometrial and endocervical adenocarcinoma preoperatively is important because the treatment is different.
3. The samples from each group are tested for HPV DNA using PCR method.
4. High risk HPV infected patients have a higher probability to become uterine cervical adenocarcinoma.
5. HPV DNA test has a role for distinguishing between uterine cervical adenocarcinoma and endometrial carcinoma.
ABSTRACT
Objectives: To analyze the role of HPV DNA for distinguishing between uterine cervical adenocarcinoma and endometrial adenocarcinoma.
Materials and Methods: This was a case control study using paraffin block samples from uterine cervix adenocarcinoma and endometrial adenocarcinoma operation at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Each group was tested for HPV DNA using PCR method. Sample size was 18 in each group.
Results: A total of 36 samples fulfilled the inclusion criteria in this study. Each group comprised 18 samples. There were 83.3% of uterine cervical adenocarcinoma and 11.1% of endometrial adenocarcinoma that revealed high risk HPV. Chi-Square test result found significant correlation between high risk HPV and uterine cervical adenocarcinoma (p<0.05) with Odds Ratio (OR) 40.00 (CI 95%).
Conclusion: There was a significant correlation between high risk HPV and uterine cervix adenocarcinoma. High-risk HPV infected patients had a risk to suffer from uterine cervical adenocarcinoma compared to those with endometrial adenocarcinoma. HPV DNA test had a role for distinguishing between uterine cervical adenocarcinoma and endometrial adenocarcinoma.
Globocan IARC 2018. Indonesia fact sheet; 2018. [update 2018; cited 2018 Dec 14]. Available from: gco.iarc.fr/today/fact sheet population.
Stewart CJR, Crum CP, McCluggage WG, et al. Guidelines to aid in the distinction of endometrial and endocervical carcinomas, and the distinction of independent primary carcinomas of the endo-metrium and adnexa from metastatic spread between these and other sites. Int J Gynecol Pathol. 2019;38:75-92. doi: 10.1097/PGP.0000000000000 553.
Singh N, Hirschowitz L, Zaino R, et al. Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade), International Journal of Gynecological Patholog. 2019;38:93-113. doi: 10.1097/PGP.0000000000000524.
Staebler A, Sherman ME, Zaino RJ, et al. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. The American Journal of Surgical Pathology. 2002;26(8):998–1006. doi: 10.1097/00000478-200208000-00004.
Galic V, Schiavone MB, Herzog TJ, et al. Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest. 2013;31(7):500-4. doi: 10.3109/07357907.2013.820321.
He H, Bhosale W, Wei W, et al. MRI is highly specific in determining primary cervical versus endometrial cancer when biopsy results are inconclusive. Clin Radiol. 2013;68:1107-13. doi: 10.1016/j.crad.2013.05.095.
Ramirez P, Frumovitz M, Milam M, et al. Limited utility of magnetic resonance imaging in determining the primary site of disease in patients with inconclusive endometrial biopsy. Int J of Gynecol Cancer. 2010;20:1344-9. doi: 10.1111/ IGC.0b013e3181f30c1b.
Chan CK, Aimagambetova G, Ukybassova T, et al. Human papillomavirus infection and cervical cancer: Epidemiology, screening, and vaccination-review of current perspectives. J Oncol. 2019; 2019. doi: 10.1155/2019/3257939.
International Agency for Research on Cancer [Internet]. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 100B. Human Papillomaviruses. Lyon, France: IARC; 2012 [update 2012; cited 2018 Sep 23]. Available from: http://monographs.iarc.fr/ENG/ Monographs/ vol100B/mono100B.pdf.
Mustafa RA, Nancy Santesso N, Khatib R, et al. Systematic reviews andmeta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy. International Journal of Gynecology and Obstetrics. 2016; 132:259–65. doi: 10.1016/j.ijgo.2015.07.024.
Olesen TB, Svahn MF, Faber MT, et al. Prevalence of human papillomavirus in endometrial cancer: a systematic review and metaanalysis. Gynecol Oncol. 2014;30:1-9. doi: 10.1016/j.ygyno.2014.02. 040.
Mastutik G, Alia R, Rahniayu A, et al. Genotyping of human papillomavirus in cervical precancerous lesion and squamous cell carcinoma at Dr Soetomo Hospital, Surabaya, Indonesia. Afr J Infect Dis. 2018;12:7-12. doi: 10.21010/Ajid.12v1S.2.
FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014;125(2): 97-8. doi: 10.1016/j.ijgo.2014.02.003.
Fedrizzi EN, Villa LL, de Souza IV, et al. Does human papillomavirus play a role in endometrial cancinogenesis? Int J Gynecol pathol. 2009;28(4): 322-27. doi: 10.1097/PGP.0b013e318199943b.
Giatromanolaki A, Sividis E, Papazoglou D, et al. Human papillomavirus in endometrial adenocarci-nomas: Infectious agent or a mere ”passanger”? Infectious Disease in Obstetrics and Gynecology. 2007;60549. doi: 10.1155/2007/60549.
1. Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
2. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
3. The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
